Journal Watch
Monday, November 7th, 2022Matching therapies to subtypes of EGFR-mutated lung cancer New research from Vanderbilt investigators suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small cell lung cancers. EGFR exon 19 deletion mutations are the most common EGFR mutations in patients with lung cancer. However, the term “exon 19 […]